U.S. Markets closed

ChromaDex Corporation (CDXC)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
4.00-0.30 (-6.98%)
At close: 4:00PM EDT
People also watch
Full screen
Previous Close4.30
Bid3.83 x 1000
Ask5.00 x 200
Day's Range3.83 - 4.40
52 Week Range2.25 - 4.85
Avg. Volume299,830
Market Cap192.24M
PE Ratio (TTM)-19.70
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube10 days ago

    ETFs with exposure to Chromadex Corp. : September 14, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Chromadex Corp. Here are 5 ETFs with the largest exposure to CDXC-US. Comparing the performance and risk of Chromadex Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Chromadex Corp. :CDXC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
    Capital Cube11 days ago

    Chromadex Corp. :CDXC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017

    Categories: Yahoo FinanceGet free summary analysis Chromadex Corp. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Chromadex Corp. – Opexa Therapeutics, Inc., Sangamo Therapeutics, Inc. and Exelixis, Inc. (OPXA-US, SGMO-US and EXEL-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD ... Read more (Read more...)

  • American City Business Journalslast month

    LabCorp purchases analytical testing services business in $8.5 million deal

    Laboratory Corporation of America Holdings (LH) has agreed to purchase ChromaDex Corp.’s analytical testing services business in a $8.5 million deal. ChromaDex, based in Irvine, Calif., announced the agreement on Wednesday, saying that the analytical testing services will now be offered through LabCorp’s Covance Food Solutions business. “The analytical testing services business was a critical component to helping further set the standard for quality and safety in the supplement industry,” said Frank Jaksch, chief executive officer of ChromaDex.